RecipharmCobra gets patents for yield-boosting plasmid tech

By Gareth Macdonald

- Last updated on GMT

Related tags Dna

RecipharmCobra Biologics has received US and EU patent protection for an antibiotic resistance gene-free plasmid maintenance technology it claims can boost biomanufacturing yields.

The system, known as oriSelect, uses a modified E.coli strain that only grows in the presence of plasmids containing the “origin of replication” pMB1 gene, eliminating the need to include additional genes to act as selection markers.

This means the oriSelect plasmids are smaller, and therefore more stably replicated during cell division, than those used in other systems that require some form of maker gene to identify successfully transfected clones.

A company spokesman told Outsouring-pharma that this will benefit manufacturing efficiency and yields, explaining that: “A smaller plasmid means more molecules per gramme​.”

For recombinant protein expression, there will theoretically be an increase due to the absence of an additional expressed gene, the antibiotic resistance gene, so we will test this when the final production strains are constructed.

He added that oriSelect “could replace any conventional antibiotic-selected DNA or protein expression system in E. coli​,” and suggested its main will be contract manufacturing projects where the absence of antibiotics is critical.

Resistance transfer

The additional benefit of oriSelect, in common with RecipharmCobra’s other genetic engineering technology platform ORT, is that it removes the risk that antibiotic resistance genes used for selection purposes are passed on to other bacteria.

This point was stressed by company VP Simon Saxby, who said that: “Antibiotic resistance gene transfer is an area of concern where oriSELECT and ORT can provide a state-of-the-art solution.”

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us


View more